Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Molecular Assessment and Profiling of Liver Transplant Recipients
NCT04793360 · View on ClinicalTrials.gov ↗
Study Summary
The objective of this protocol is to conduct longitudinal and prospective studies of liver transplant recipients, using a multimodality approach, akin to that used in kidney transplantation. The primary aim will compare the clinical outcomes of LiverCare post-transplant surveillance in liver transplant with standard of care consisting of liver function tests, DSA measurements, drug level monitoring, and 'for cause' biopsy. The protocol will assess the correlation between clinical events (e.g. rejection, recurrent disease, biliary obstruction), dd-cfDNA levels, gene expression profiling, ability to assess microchimerism, develop predictive analytics, infectious disease diagnoses and finally examine graft histology.
Conditions Studied
Interventions
- DEVICE LiverCare
Study Locations (20)
Massachusetts
- Massachusetts General Hospital — Boston
- Beth Israel Deaconess Medical Center (BIDMC) — Boston
Michigan
- University of Michigan — Ann Arbor
- Henry Ford Health System — Detroit
New York
- Icahn School of Medicine at Mount Sinai — New York
- Westchester Medical Center — Valhalla
North Carolina
- Atrium Health — Charlotte
- Duke University — Durham
California
- Keck Medical Center of USC — Los Angeles
District of Columbia
- MedStar Georgetown University Hospital — Washington D.C.
Florida
- Tampa General Hospital — Tampa
Georgia
- Piedmont Healthcare — Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,500 participants |
| Start Date | 2021-05-26 |
| Est. Completion | 2028-03-31 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04793360
The ClinicalTrials.gov registry entry for NCT04793360 describes a study currently listed as active not recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 1,500 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CareDx, which has 5 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 2 conditions, with Liver Transplantation appearing as the primary indexed condition, and to 1 intervention — of which LiverCare is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT04793360 reports 20 study locations spanning 16 distinct geographic areas — top geographies include Massachusetts, Michigan, New York. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT04793360 about?
NCT04793360 is a clinical study titled "Molecular Assessment and Profiling of Liver Transplant Recipients". The objective of this protocol is to conduct longitudinal and prospective studies of liver transplant recipients, using a multimodality approach, akin to that used in kidney transplantation. The primary aim will compare the clinical outcomes of LiverCare post-transplant surveillance in liver transpl...
What is the current status of trial NCT04793360?
This trial is currently active not recruiting. The enrollment target is 1,500 participants. The study started on 2021-05-26. Estimated completion is 2028-03-31.
What conditions does trial NCT04793360 study?
This clinical trial studies the following conditions: Liver Transplantation, Biomarkers. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT04793360?
The interventions under investigation include: LiverCare (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT04793360?
This trial is sponsored by CareDx, which has 5 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT04793360 being conducted?
This trial has 20 study locations across California, District of Columbia, Florida, Georgia, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.